China Biotech Services raises Jiabao Zhongzhi’s subscription in Pengbo (Hainan) to RMB9.45 million

Bulletin Express
06/16

Hong Kong – 16 June 2026 – China Biotech Services Holdings Limited (“China Biotech Services”) announced a supplemental agreement that increases the amount Jiabao Zhongzhi (Hainan) will invest in the registered capital of subsidiary Pengbo (Hainan) from RMB9.30 million to RMB9.45 million. The revised commitment represents approximately 5.93% of Pengbo (Hainan)’s enlarged registered capital upon completion of the 2026 Subscription.

The adjustment, agreed among Dynamic Healthcare, Jiabao Zhongzhi (Hainan) and Pengbo (Hainan), is intended to accommodate additional staff participants under Pengbo (Hainan)’s Share Award Scheme. All other terms of the original Tripartite Agreement dated 15 May 2026 remain unchanged.

Following completion, China Biotech Services will continue to hold its controlling 94.07% stake in Pengbo (Hainan) through its wholly owned subsidiaries, while Jiabao Zhongzhi (Hainan) retains the 5.93% minority interest. The transaction will be accounted for as an equity transaction with no gain or loss recognised in the group’s consolidated statement of profit or loss and other comprehensive income, and management expects no material financial impact.

Regulatory Review • Under Rule 19.32A(1) of the GEM Listing Rules, all applicable percentage ratios remain below 5%, classifying the deal as a non-notifiable transaction. • As Jiabao Zhongzhi (Hainan) director Mr. Li is a connected person at the subsidiary level, the subscription constitutes a connected transaction. However, it qualifies for reporting and announcement exemptions from circular, independent financial advice and independent shareholders’ approval requirements under Rule 20.99. • The board, including all independent non-executive directors, has confirmed that the transaction terms are fair, reasonable and in the interests of shareholders as a whole.

Corporate Governance No director holds any material interest in the supplemental agreement, and none were required to abstain from the board vote.

China Biotech Services, listed on GEM of the Hong Kong Stock Exchange (stock code: 08037), states that Pengbo (Hainan) will remain consolidated in the group accounts post-transaction.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10